3-MeO-PCP is a dissociative anesthetic with effects that are compared to PCP and ketamine. It is an NMDA receptor antagonist. It has been available in online research chemical markets since 2010, with wide distribution beginning in 2011. Because it is less physically sedating than ketamine, strong doses of it can cause ambulatory delirious states during which users may not realize they are unable to differentiate reality from fantasy. At least one confirmed death has been associated with its use.